Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.72 |
| ▸ | KIT | P10721 | 4/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765894 | 0.86 | ABL1 (0.85) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL13771744 | 0.86 | KIT (0.58) | ABL1KIT | |
| SCHEMBL15006468 | 0.84 | KIT (0.70) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL13765896 | 0.83 | ABL1 (0.73) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL31620766 | 0.83 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL4100122 | 0.83 | ABL1 (0.71) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL31620735 | 0.81 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL16250590 | 0.81 | KIT (0.82) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL19891571 | 0.81 | KIT (0.72) | ABL1KITFGFR1PDGFRAFLT3 | |
| SCHEMBL22548931 | 0.81 | ABL1 (1.00) | ABL1KITFGFR1CYP2C9PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090561-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2007133560-A9 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | ABL1 1035/4885KIT 3086/4885FGFR1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.